Tratamiento del síndrome antifosfolipídico en mujeres embarazadas

Abstract

Introduction: Antiphospholipid syndrome is an autoimmune disease characterized by arterial, venous or small vessel thrombosis. It is also associated with pregnancy due to recurrent early pregnancy loss, fetal loss, preeclampsia, pregnancy loss, thromboembolism, premature birth and perinatal mortality. due to the presence of positive antiphospholipid antibodies. Treatment to prevent recurrent obstetric complications consists of low doses of acetylsalicylic acid (ASA) and prophylactic heparin (LMWH). Without treatment, only 25% of patients with antiphospholipid syndrome give birth to a healthy newborn. This figure has improved to around 70% with the introduction of low doses of acetylsalicylic acid and treatment with low molecular weight heparin. Objective: Investigate the treatment of antiphospholipid syndrome through critical reading of high-impact scientific articles to propose an appropriate treatment. Methodology: a descriptive research was carried out through bibliographic review in scientific database search platforms such as Pubmed, Mesh and Cochrane about the treatment of antiphospholipid syndrome in pregnant women. Conclusions: Early administration of adequate therapeutic management such as acetylsalicylic acid plus low molecular weight heparin significantly reduces early pregnancy loss. Therefore, high-quality, large-scale randomized clinical trials and further research on antiphospholipid syndrome in pregnancy are needed to identify the most appropriate treatment protocol in each patient.